Cargando…

Clinical considerations for the design of PROTACs in cancer

Degradation of targeted proteins using proteolysis targeting chimeras (PROTACs) has gained momentum. A PROTAC is a bifunctional molecule that consists of three parts: a ligand that interacts with the protein to be degraded, another ligand that binds to an E3 ubiquitin ligase and a linker that connec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nieto-Jiménez, Cristina, Morafraile, Esther Cabañas, Alonso-Moreno, Carlos, Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900451/ https://www.ncbi.nlm.nih.gov/pubmed/35249548 http://dx.doi.org/10.1186/s12943-022-01535-7

Ejemplares similares

Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers
por: Morafraile, Esther Cabañas, et al.
Publicado: (2023)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
por: Juan, Alberto, et al.
Publicado: (2022)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
por: Cimas, Francisco J., et al.
Publicado: (2020)

Are we ready to design oral PROTACs®?
por: Jimenez, Diego Garcia, et al.
Publicado: (2021)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)

Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2022)

Genomic Correlates of DNA Damage in Breast Cancer Subtypes
por: Cabañas Morafraile, Esther, et al.
Publicado: (2021)

PROTACs in the Management of Prostate Cancer
por: Yedla, Poornachandra, et al.
Publicado: (2023)

Genomic mapping of copy number variations influencing immune response in breast cancer
por: López-Cade, Igor, et al.
Publicado: (2022)

Designing Soluble PROTACs: Strategies and Preliminary Guidelines
por: García Jiménez, Diego, et al.
Publicado: (2022)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Small-Molecule PROTACs for Cancer Immunotherapy
por: Liu, Zefan, et al.
Publicado: (2022)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Current strategies for the design of PROTAC linkers: a critical review
por: Troup, Robert I., et al.
Publicado: (2020)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents
por: del Campo-Balguerías, Almudena, et al.
Publicado: (2023)

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019)

Structure‐Based Design of a Macrocyclic PROTAC
por: Testa, Andrea, et al.
Publicado: (2019)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Considerations for the clinical development of immuno-oncology agents in cancer
por: Pandiella, Atanasio, et al.
Publicado: (2023)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

Antiviral PROTACs: Opportunity borne with challenge
por: Liang, Jinsen, et al.
Publicado: (2023)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
por: Liu, Xuelian, et al.
Publicado: (2023)

PROTACs: A novel strategy for cancer drug discovery and development
por: Han, Xin, et al.
Publicado: (2023)

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
por: Kelm, Jeremy M., et al.
Publicado: (2023)

PROTACs: great opportunities for academia and industry
por: Sun, Xiuyun, et al.
Publicado: (2019)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

Recent Advances in PROTAC-Based Antiviral Strategies
por: Ahmad, Haleema, et al.
Publicado: (2023)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
por: Farnaby, William, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u07rh0p5eib6o5cs4s981glr0s